Botulinum Toxin Dosing via Neuromuscular Junction Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing regimens for botulinum toxin administration are imprecise, leading to overdosing and undesirable side effects due to reliance on body weight and muscle size, which does not accurately reflect the number of neuromuscular junctions, resulting in variable efficacy and increased costs.
Innovation Solution
A novel dosing method based on the number and distribution of neuromuscular junctions in the target muscle, using ultrasonography to determine the appropriate therapeutic dose and injection sites, ensuring that only the necessary amount of toxin is used to achieve the desired effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If dosing is based on body weight and muscle size, then dosing is simple to administer, but dosing precision is insufficient leading to overdosing and side effects
Solution Approach 1:
The patent changes the dosing parameter from body weight/muscle size to the number of neuromuscular junctions (NMJs) in the target muscle. This parameter change enables precise dosing by directly correlating toxin units to the actual number of targets (NMJs), thereby resolving the contradiction between ease of administration and dosing precision.
2Reliability
If higher dose of botulinum toxin is administered, then efficacy is improved, but harmful factors increase due to overdosing and side effects
Solution Approach 1:
The patent employs a feedback mechanism where the calculated number of NMJs in the target muscle provides information about the precise toxin dose required. This feedback loop ensures that the administered dose matches the actual target burden, maximizing efficacy while preventing harmful overdosing effects.
Solution Approach 2:
The patent applies the principle of partial action by administering only the precise amount of toxin needed to saturate the NMJs in the target muscle, rather than using excessive doses. This ensures therapeutic effectiveness while minimizing harmful side effects from unnecessary toxin exposure.
3Ease of manufacture
If dosing is based on body weight, then dosing protocol is simple, but manufacturing precision of therapeutic effect is poor
Solution Approach 1:
The patent transforms the dosing parameter from body weight to NMJ count, which directly reflects the therapeutic target. This parameter change ensures consistent therapeutic effects across patients of different sizes, as the dose is tailored to the actual number of NMJs rather than a proxy measure like body weight.
4Volume of moving object
If larger volume of toxin is injected, then distribution is improved, but loss of substance increases due to diffusion to non-target areas
Solution Approach 1:
The patent applies local quality by concentrating the toxin injection precisely at the location of the NMJs in the target muscle, rather than distributing it broadly. This localized approach ensures that the toxin acts where needed while preventing diffusion to non-target areas, thereby reducing substance loss and off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach minimizes side effects, improves efficacy, and reduces costs by ensuring precise delivery of botulinum toxin directly to neuromuscular junctions, maintaining effectiveness while avoiding unnecessary toxin exposure and immune challenges.
Implementation Method 1
using ultrasonography to determine the appropriate therapeutic dose and injection sites
Data Source
AI summary
A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight.